AR044475A1 - Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades - Google Patents
Derivados de 2-amino -piridina utiles para el tratamiento de enfermedadesInfo
- Publication number
- AR044475A1 AR044475A1 ARP040101904A ARP040101904A AR044475A1 AR 044475 A1 AR044475 A1 AR 044475A1 AR P040101904 A ARP040101904 A AR P040101904A AR P040101904 A ARP040101904 A AR P040101904A AR 044475 A1 AR044475 A1 AR 044475A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- optionally substituted
- independently selected
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Procedimientos para prepararlos, composiciones que los contienen y usos de dichos derivados, Los compuestos son útiles en numerosas enfermedades, en particular enfermedades, trastornos y afecciones inflamatorias, alérgicas y respiratorias. Reivindicación 1: Un compuesto de fórmula (1) en la que el grupo (CH2)n-C(=O)Q1 está en la posición meta o para, R1 y R2 se seleccionan independientemente entre H y alquilo C1-4, n es 0, 1 ó 2 y Q1 es un grupo seleccionado entre los compuestos de fórmulas (2) y un grupo *-NR-Q2-A, donde p es 1, 2 ó 3, q es 1 ó 2, Q2 es un enlace directo o un alquileno C1-4 opcionalmente sustituido con OH, R es H, alquilo C1-4 o fenilo opcionalmente sustituido con OH y A es cicloalquilo C3-7, estando dicho cicloalquilo opcionalmente unido mediante uno o más átomos de C, preferiblemente 1 o 2 átomos de C, tetrahidropiranilo, piperidinilo, tetrahidrotiopiranilo, piridilo o un grupo seleccionado entre el grupo de fórmula (3) donde R3, R4, R5, R6 y R7 son iguales o diferentes y cada uno se selecciona independientemente entre H, alquilo C1-4, OR9, SR9, halo, CF3, OCF3, (CH2)mCOOR9, SO2NR8R9, CONR8R9, NR8R9, NHCOR8, SO2-alquilo (C1-4) y fenilo opcionalmente sustituido con hidroxi o hidroxi-alquilo (C1-4); donde m es un número entero seleccionado entre 0, 1 y 2 y R8 y R9 son iguales o diferentes y se seleccionan independientemente entre H o alquilo C1-4 y el * representa el punto de unión al grupo carbonilo; o, si es apropiado, sus sales y/o isómeros, tautómeros, solvatos o variaciones isotópicas farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0312832.9A GB0312832D0 (en) | 2003-06-04 | 2003-06-04 | 2-amino-pyridine derivatives useful for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044475A1 true AR044475A1 (es) | 2005-09-14 |
Family
ID=9959308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101904A AR044475A1 (es) | 2003-06-04 | 2004-06-03 | Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1633715B1 (es) |
| JP (1) | JP2006526613A (es) |
| AR (1) | AR044475A1 (es) |
| AT (1) | ATE372321T1 (es) |
| BR (1) | BRPI0410946A (es) |
| CA (1) | CA2527788A1 (es) |
| CL (1) | CL2004001366A1 (es) |
| DE (1) | DE602004008773T2 (es) |
| ES (1) | ES2291882T3 (es) |
| GB (1) | GB0312832D0 (es) |
| GT (1) | GT200400116A (es) |
| MX (1) | MXPA05012840A (es) |
| NL (1) | NL1026329C2 (es) |
| PA (1) | PA8604301A1 (es) |
| PE (1) | PE20050628A1 (es) |
| TW (1) | TW200524603A (es) |
| UY (1) | UY28339A1 (es) |
| WO (1) | WO2004108676A1 (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| CN101083982A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物 |
| WO2006034440A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| CN101084211A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为治疗剂的用途 |
| TW200626139A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| WO2006034441A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| CA2618089A1 (en) | 2005-08-08 | 2007-02-15 | Argenta Discovery Ltd. | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| PT2013211E (pt) | 2006-04-21 | 2012-06-21 | Novartis Ag | Derivados de purina para utilização como agonistas de receptores a2a de adenosina |
| ES2392999T3 (es) * | 2006-06-09 | 2012-12-17 | Parion Sciences, Inc. | Bloqueadores de canales de sodio pirazinoilguanidina sustituida con fenilo que tienen actividad agonista beta |
| US8470859B2 (en) | 2006-10-23 | 2013-06-25 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
| ATE499363T1 (de) | 2007-05-07 | 2011-03-15 | Novartis Ag | Organische verbindungen |
| WO2009074575A2 (en) | 2007-12-10 | 2009-06-18 | Novartis Ag | Organic compounds |
| ES2442930T3 (es) | 2008-01-11 | 2014-02-14 | Novartis Ag | Pirimidinas como inhibidores de cinasas |
| US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
| BRPI0915018A2 (pt) | 2008-06-10 | 2015-10-27 | Novartis Ag | compostos orgânicos |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| DE102008049675A1 (de) | 2008-09-30 | 2010-04-01 | Markus Dr. Heinrich | Verfahren zur Herstellung von 3-Aminobiphenylen |
| EP2379507B1 (en) | 2008-12-30 | 2013-10-16 | Pulmagen Therapeutics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| US10004732B2 (en) | 2014-04-24 | 2018-06-26 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| CA2945069A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| JP2022537667A (ja) | 2019-06-10 | 2022-08-29 | ノバルティス アーゲー | Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体 |
| AU2020338971B2 (en) | 2019-08-28 | 2023-11-23 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| US5977124A (en) * | 1995-05-10 | 1999-11-02 | Pfizer Inc. | β-adrenergic agonists |
| EP1078924B1 (en) * | 1999-07-23 | 2004-10-20 | Pfizer Products Inc. | Intermediates and a process for producing beta-adrenergic receptor agonists |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0217225D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| EA200500618A1 (ru) * | 2002-10-11 | 2005-12-29 | Пфайзер Инк. | Производные индола в качестве бета-2 агонистов |
-
2003
- 2003-06-04 GB GBGB0312832.9A patent/GB0312832D0/en not_active Ceased
-
2004
- 2004-06-01 DE DE602004008773T patent/DE602004008773T2/de not_active Expired - Fee Related
- 2004-06-01 MX MXPA05012840A patent/MXPA05012840A/es unknown
- 2004-06-01 WO PCT/IB2004/001850 patent/WO2004108676A1/en active IP Right Grant
- 2004-06-01 PE PE2004000553A patent/PE20050628A1/es not_active Application Discontinuation
- 2004-06-01 ES ES04735621T patent/ES2291882T3/es not_active Expired - Lifetime
- 2004-06-01 AT AT04735621T patent/ATE372321T1/de not_active IP Right Cessation
- 2004-06-01 CA CA002527788A patent/CA2527788A1/en not_active Abandoned
- 2004-06-01 JP JP2006508431A patent/JP2006526613A/ja not_active Withdrawn
- 2004-06-01 BR BRPI0410946-5A patent/BRPI0410946A/pt not_active IP Right Cessation
- 2004-06-01 EP EP04735621A patent/EP1633715B1/en not_active Expired - Lifetime
- 2004-06-02 UY UY28339A patent/UY28339A1/es not_active Application Discontinuation
- 2004-06-03 CL CL200401366A patent/CL2004001366A1/es unknown
- 2004-06-03 GT GT200400116A patent/GT200400116A/es unknown
- 2004-06-03 TW TW093115990A patent/TW200524603A/zh unknown
- 2004-06-03 PA PA20048604301A patent/PA8604301A1/es unknown
- 2004-06-03 AR ARP040101904A patent/AR044475A1/es unknown
- 2004-06-03 NL NL1026329A patent/NL1026329C2/nl not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004008773D1 (de) | 2007-10-18 |
| PE20050628A1 (es) | 2005-08-30 |
| JP2006526613A (ja) | 2006-11-24 |
| CL2004001366A1 (es) | 2005-05-06 |
| EP1633715B1 (en) | 2007-09-05 |
| CA2527788A1 (en) | 2004-12-16 |
| ATE372321T1 (de) | 2007-09-15 |
| TW200524603A (en) | 2005-08-01 |
| EP1633715A1 (en) | 2006-03-15 |
| ES2291882T3 (es) | 2008-03-01 |
| NL1026329C2 (nl) | 2005-07-26 |
| PA8604301A1 (es) | 2004-12-16 |
| DE602004008773T2 (de) | 2008-01-10 |
| GT200400116A (es) | 2005-03-03 |
| WO2004108676A1 (en) | 2004-12-16 |
| MXPA05012840A (es) | 2006-02-13 |
| GB0312832D0 (en) | 2003-07-09 |
| NL1026329A1 (nl) | 2004-12-07 |
| UY28339A1 (es) | 2005-01-31 |
| BRPI0410946A (pt) | 2006-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044475A1 (es) | Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades | |
| AR047509A1 (es) | Derivados de sulfonamida como antagonistas de receptores adrenergicos beta2 | |
| AR047510A1 (es) | Derivados de sulfonamida como agonistas de receptores adrenergicos ??2 | |
| AR044476A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR069326A1 (es) | Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
| AR038834A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR037676A1 (es) | Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion; composicion farmaceutica que los comprende y procedimiento para preparar compuestos de formula (i) | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| CO5700776A2 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
| RS53108B (en) | AMINO-1,3,5-TRIAZINES N-REPLACED BY CHIRAL BICYCLIC RADICALS, THE PROCESS FOR THEIR PREPARATION, THEIR COMPOUNDS AND THEIR APPLICATIONS AS HERBICIDES AND PLANT GROWTH REGULATORS | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR048322A1 (es) | Compuestos para el tratamiento de afecciones inflamatorias, alergicas y respiratorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |